Showing results (61-70 of 113) with videos related to

Sort By:
Pageof 12
Clinical Pharmacokinetics|February 2, 2021
Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and RaltegravirXiaomei I Liu, Jeremiah D Momper, Natella Y Rakhmanina, et al.
The Pediatric Infectious Disease Journal|August 18, 2022
Maraviroc Population Pharmacokinetics Within the First 6 Weeks of LifeMarlon Liyanage, Mina Nikanjam, Lynn McFadyen, et al.
JAMA|July 4, 2002
Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trialAlejandro Dorenbaum, Coleen K Cunningham, Richard D Gelber, et al.
Clinical Pharmacokinetics|May 27, 2020
Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic ModelingXiaomei I Liu, Jeremiah D Momper, Natella Y Rakhmanina, et al.
The Pediatric Infectious Disease Journal|November 1, 2016
Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057Luiz Eduardo Osorio, Maria Ines Boechat, Mark Mirochnick, et al.
Frontiers in Pediatrics|November 1, 2021
Characterization of Plasma Protein Alterations in Pregnant and Postpartum Individuals Living With HIV to Support Physiologically-Based Pharmacokinetic Model DevelopmentSherry Zhao, Mary Gockenbach, Manuela Grimstein, et al.
Journal of Clinical Pharmacology|December 17, 2025
Population Pharmacokinetics of Bictegravir During Pregnancy and Postpartum: Role of Adherence in Maintaining Therapeutic ExposureSteven Sun, Mina Nikanjam, Mark Mirochnick, et al.
The Journal of Antimicrobial Chemotherapy|February 5, 2019
Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modellingStein Schalkwijk, Rob Ter Heine, Angela Colbers, et al.
The Lancet. HIV|July 17, 2019
Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research prioritiesSharon Nachman, Claire L Townsend, Elaine J Abrams, et al.
The Pediatric Infectious Disease Journal|January 8, 2024
Safety and Pharmacokinetics of Lopinavir/Ritonavir Oral Solution in Preterm and Term Infants Starting Before 3 Months of AgeAdrie Bekker, Jincheng Yang, Jiajia Wang, et al.
Pageof 12